Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ischaemic Myocardial Dysfunction Clear all
Completed Phase 2 Interventional Results available

Rilonacept to Improve Artery Function in Patients With Atherosclerosis

NCT00417417
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Crossover Trial of Clopidogrel and Ticagrelor

NCT03161678
View directory record Official record
Conditions
Myocardial Infarction, Thrombosis, Platelet Dysfunction
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

NCT06699056
View directory record Official record
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Completed No phase listed Observational

Vascular Inflammation in Adolescents With Type 1 Diabetes

NCT00933101
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Sep 2, 2026, 6:33 AM EDT
Active, not recruiting Not applicable Interventional

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

NCT04763200
View directory record Official record
Conditions
Left Ventricular Dysfunction, Coronary Artery Disease
Interventions
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 3 Interventional Results available

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

NCT02924727
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 2, 2026, 6:33 AM EDT
Not yet recruiting Phase 2 Interventional

Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

NCT07118449
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
XC001, A195/placebo
Drug
Lead sponsor
XyloCor Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 2, 2026, 6:33 AM EDT
Recruiting No phase listed Observational

Identification of Genomic Predictors of Adverse Events After Cardiac Surgery

NCT01258231
View directory record Official record
Conditions
Heart; Dysfunction Postoperative, Cardiac Surgery, Genetic Predisposition to Disease, Atrial Fibrillation, Myocardial Infarction, Heart Failure
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 90 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Results available

Genomic Outcomes of Metformin

NCT02986659
View directory record Official record
Conditions
Coronary Artery Disease, Mild Cognitive Impairment, Obesity, Abdominal, Hypertension
Interventions
Metformin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 2, 2026, 6:33 AM EDT
Recruiting Not applicable Interventional

Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)

NCT07449325
View directory record Official record
Conditions
Angina Pectoris, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases, Vascular Diseases, Microvascular Angina
Interventions
A-FLUX Reducer System
Device
Lead sponsor
VahatiCor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
New Haven, Connecticut • Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Terminated Not applicable Interventional Results available

DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation

NCT00487279
View directory record Official record
Conditions
Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
Interventions
Defibrillator, Control
Device · Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
56
States / cities
Anchorage, Alaska • Tucson, Arizona • Glendale, California + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Not applicable Interventional

Analysis of Surface EKG Signals to Identify Myocardial Dysfunction in Patients at Risk for Coronary Artery Disease

NCT02560168
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
MyoVista device, Computed tomographic coronary angiography, Transthoracic Echocardiography
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Sep 2, 2026, 6:33 AM EDT
Withdrawn Phase 1Phase 2 Interventional

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

NCT02503280
View directory record Official record
Conditions
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
Interventions
Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo, Biosense Webster MyoStar NOGA Injection Catheter System
Drug · Device
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 2, 2026, 6:33 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The DISCOVER INOCA Prospective Multi-center Registry

NCT05288361
View directory record Official record
Conditions
Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography
Interventions
Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2032
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

Assessment of Coronary Plaque Composition Using Optical Coherence Tomography

NCT01642173
View directory record Official record
Conditions
Coronary Atherosclerosis, Endothelial Dysfunction, Coronary Small Vessel Disease
Interventions
Optical Coherence Tomography (C7 XR Dragonfly )
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2016 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CES1 Carriers in the PAPI Study

NCT03188705
View directory record Official record
Conditions
Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases, Myocardial Ischemia, Artery Occlusion, Aspirin Sensitivity, Clopidogrel, Poor Metabolism of, Platelet Dysfunction, Platelet Thrombus
Interventions
Clopidogrel, Aspirin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)

NCT00587990
View directory record Official record
Conditions
Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions
Lower dose mesenchymal stem cell (MSC) injection, Placebo, Higher dose MSC injection
Biological · Genetic
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 2, 2026, 6:33 AM EDT
Completed No phase listed Observational

Uric Acid Levels and Endothelial Functions

NCT02862522
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Questionnaire of overall health
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older · Female only
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Sep 2, 2026, 6:33 AM EDT
Not listed Phase 1 Interventional

VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study

NCT00512005
View directory record Official record
Conditions
Mitral Valve Regurgitation, Left Ventricular Dysfunction, Heart Failure, Mitral Insufficiency, Mitral Incompetence, Ischemic Heart Disease
Interventions
Percutaneous mitral valve repair
Device
Lead sponsor
Myocor
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • Evanston, Illinois • Shawnee Mission, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2009 · Synced Sep 2, 2026, 6:33 AM EDT
Withdrawn No phase listed Observational

RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain

NCT03257683
View directory record Official record
Conditions
Severe Coronary Artery Disease, Ischaemic Myocardial Dysfunction
Interventions
Ranolazine
Drug
Lead sponsor
Saint Thomas Health
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Not applicable Interventional Results available

Vitamin D Repletion in Coronary Artery Disease

NCT01570309
View directory record Official record
Conditions
Vitamin D Deficiency, Coronary Artery Disease, Endothelial Dysfunction, Inflammation
Interventions
Ergocalciferol, Sugar pill
Drug · Other
Lead sponsor
Seth I. Sokol, M.D.
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systolic Blood Pressure Intervention Trial

NCT01206062
View directory record Official record
Conditions
Hypertension
Interventions
Intensive control of SBP, Standard control of SBP
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
50 Years and older
Enrollment
9,361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 2, 2026, 6:33 AM EDT
Enrolling by invitation Not applicable Interventional

SHADES Mechanistic Trial

NCT06041581
View directory record Official record
Conditions
Insomnia, Insomnia Chronic, Insomnia, Primary, Sleep Disturbance, Sleep Disorder, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke, Autonomic Dysfunction, Systemic Inflammatory Response, Metabolic Disease
Interventions
Sleep Healthy Using The Internet (SHUTi), Telephonic CBT-I, Face-to-Face CBT-I, Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care
Behavioral · Other
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 2, 2026, 6:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

NCT04776239
View directory record Official record
Conditions
Diabetes Mellitus, Ischemic Heart Disease
Interventions
100 million Allogeneic Mesenchymal Human Stem Cells, Placebo
Drug · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 2, 2026, 6:33 AM EDT